Full Press Release Details
IDEAYA Biosciences Reports End of Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single Arm Trial Design for Potential Phase 2 Registration Enabling Study in Metastatic Uveal Melanoma.
IDYA
IDEAYA Biosciences Reports End of Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single Arm Trial Design for Potential Phase 2 Registration Enabling Study in Metastatic Uveal Melanoma
Key Takeaway: IDEAYA Biosciences Reports End of Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single Arm Trial Design for Potential Phase 2 Registration Enabling Study in Metastatic Uveal Melanoma
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma